Ranolazine Tablet, Extended Release
FDA Recall NDC 27241-125
Latest: Class II · Status: Ongoing · Initiated Sep 17, 2026 · 1 enforcement report
Active & Historical Enforcement Reports
The FDA has identified 1 recorded enforcement report(s) associated with Ranolazine (NDC 27241-125). A significant event, classified as Class II, was initiated on Sep 17, 2026 by Ajanta Pharma Usa Inc.. The reported reason for this action was: "Failed Dissolution Specifications: below specification"
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
Reported Recall Events
Class II Ongoing
Failed Dissolution Specifications: below specification
Sep 17, 2026
Oct 07, 2026
N/A
Recall Profile & Regulatory Data
Event ID
99893
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Ajanta Pharma USA Inc
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the US.
Product Description
Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807. NDC: 27241-126-02
Batch or Lot Expiration Information
Lot# Lot: DJ25134, Exp 11/30/2028
Affected Packages Involved in this Recall
27241-125-02Ranolazine
27241-125-05Ranolazine
27241-126-02Ranolazine
27241-126-05Ranolazine
About FDA Recall Enforcement Reports
FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.
If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.